ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
NYSE:ADCT
Price:
4.76 USD
-4.03%
Market Closed
Updated:
Apr 19, 2024
ADC Therapeutics SA
Total Current Liabilities
Last
Value
3-Years CAGR
5-Years CAGR
|
ADC Therapeutics SA
Total Current Liabilities Peer Comparison
Comparables:
ACIU
CRSP
BSLN
IDIA
KURN
Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Total Current Liabilities
$67.7m
|
CAGR 3-Years
19%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Total Current Liabilities
CHf13.6m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Total Current Liabilities
$108.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Total Current Liabilities
CHf47.6m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-2%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Total Current Liabilities
CHf170.4m
|
CAGR 3-Years
15%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Total Current Liabilities
CHf13.2m
|
CAGR 3-Years
50%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Total Current Liabilities?
Total Current Liabilities
67.7m
USD
67.7m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Total Current Liabilities amounts to 67.7m USD.
What is ADC Therapeutics SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
25%
25%
Over the last year, the Total Current Liabilities growth was -32%. The average annual Total Current Liabilities growth rates for ADC Therapeutics SA have been 19% over the past three years , 25% over the past five years .
You don't have any saved screeners yet
